Question explored with the scientific record
were ivermectin and hydroxicloriquine shown to be good against covid? A. the evidence shows they were great for fighting covid. B. inconcluseive/unsure/could go either way. C. evidence shows they were innefective
The short version: the best evidence from large randomized trials shows neither ivermectin nor hydroxychloroquine provided meaningful benefit for COVID-19, but the story is more complicated than "ineffective."
The most reliable evidence comes from a 2025 meta-analysis of 23 randomized trials with 12,345 patients, which found ivermectin had no statistically significant effect on viral clearance, hospitalization duration, or symptom resolution [5]. A 2020 meta-analysis of hydroxychloroquine for nonsevere COVID-19 found it did not improve clinical outcomes, viral clearance, or mortality, and it increased gastrointestinal side effects [4]. The large RECOVERY and SOLIDARITY trials, cited in a 2025 review, showed hydroxychloroquine was associated with increased mortality in pooled analyses [12].
But the picture is not clean. Early treatment timing matters. A meta-analysis of five randomized trials found that hydroxychloroquine started within two days of exposure reduced the composite of infection, hospitalization, or death by 24% (RR 0.76, p=0.025) [10]. When restricted to treatment started within two days, the benefit was stronger (RR 0.68, p=0.0097) [10]. A 2021 randomized trial of ivermectin plus doxycycline found it shortened recovery time from 9 to 7 days (HR 0.73, p=0.003) and reduced disease progression [9]. A 2024 randomized trial found ivermectin reduced viral load at day 10 (p=0.028) but did not improve symptoms [8].
The observational studies that showed dramatic benefits [2, 11, 13, 16] all lack proper control groups. They compare treated patients to national averages or to people who refused treatment, which is not a valid comparison. The early French study that showed 100% viral clearance with hydroxychloroquine plus azithromycin had only 6 patients in the combination group [15].
| Drug | Best evidence type | Key finding | Confidence |
|---|---|---|---|
| Ivermectin | 23 RCT meta-analysis (2025) | No significant benefit on viral clearance, hospitalization, or symptoms [5] | High for no benefit overall |
| Ivermectin | Single RCT (2021) | Reduced recovery time from 9 to 7 days [9] | Moderate for early treatment |
| Hydroxychloroquine | Meta-analysis of 5 RCTs (2020) | 24% reduction in composite outcome when started early [10] | Moderate for early treatment |
| Hydroxychloroquine | Meta-analysis of nonsevere COVID (2020) | No benefit on mortality, viral clearance, or clinical progression [4] | High for no benefit in hospitalized |
The evidence that exists was not funded by manufacturers seeking to prove these drugs work. The problem is the opposite: most studies were small, poorly designed, or observational. The large, well-run trials found no benefit. The positive signals come from early treatment, which the large trials did not always test.
My call: for early outpatient treatment, both drugs show modest signals of benefit that the best evidence does not confirm. For hospitalized patients, the evidence clearly shows no benefit. Confidence: moderate for early treatment, high for no benefit in later disease.
Sources used 11
-
The Use of Oral Human Grade Ivermectin with Supplements Known as Immunomodulators for Treating Patients with COVID-19 Infections at Home
An ex post facto study of 338 COVID-19 patients treated at home with oral ivermectin plus immunomodulator supplements in Metro Manila reported 95.6% complete recovery and found that gender, comorbidity, shortness of breath, muscle pain, headache, combination immunomodulators, an…
DOI: 10.46889/jcim.2022.3205 -
Hydroxychloroquine for treatment of nonsevere COVID‐19 patients: Systematic review and meta‐analysis of controlled clinical trials
Hydroxychloroquine shows no net benefit for nonsevere COVID-19: it prevents early radiological progression but does not improve clinical outcomes, viral clearance, or mortality, and increases adverse effects.
DOI: 10.1002/jmv.26442 -
Repurposing Anthelmintic Drugs for COVID-19 Treatment: A Comprehensive Meta-Analysis of Randomized Clinical Trials on Ivermectin and Mebendazole
An up-to-date meta-analysis of 23 randomized trials (n = 12,345) evaluating ivermectin and mebendazole for COVID-19 found no statistically significant improvement in viral clearance, hospitalization duration, or symptom resolution overall, although some individual studies sugges…
DOI: 10.3390/antibiotics14050459 -
Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial
This study evaluates the efficacy and safety of oral ivermectin in reducing viral load in hospitalized patients with mild to moderate Covid-19, finding a statistically significant reduction in viral load but no significant impact on clinical symptoms.
DOI: 10.1186/s12879-024-09563-y -
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
Combining ivermectin with doxycycline shortened time to clinical recovery and reduced disease progression and viral persistence in adults with mild-to-moderate COVID-19 compared with placebo.
DOI: 10.1177/03000605211013550 - Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis DOI: 10.1101/2020.09.30.20204693
-
Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis
This review argues that hydroxychloroquine plus azithromycin or doxycycline, preferably with zinc, is safe and effective as early outpatient treatment for high-risk COVID-19 patients, citing non-randomized and observational evidence to prevent hospitalization.
DOI: 10.1093/aje/kwaa093 -
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question
This article critically reviews COVID-19 drug repurposing with a focus on hydroxychloroquine, ivermectin, and remdesivir, outlining the evidence, controversies, regulatory responses, and ongoing debates about their efficacy, safety, and scientific integrity.
DOI: 10.3390/v17070881 -
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection
In a retrospective series of 320 high-risk outpatients with suspected or confirmed COVID-19 treated with empiric multidrug therapy, hospitalization occurred in 6 (1.9%) and death in 1 (0.3%), suggesting low event rates but lacking a control group.
DOI: 10.31083/j.rcm.2020.04.260 -
Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19
Azithromycin shows in vitro antiviral activity against SARS-CoV-2 with EC50 2.12 μM, but clinical evidence from non-randomized studies is mixed and no well-controlled trial supports its use in COVID-19.
DOI: 10.1002/cpt.1857 -
Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy
Early outpatient treatment of COVID-19 with combined anti-inflammatory, antiplatelet, and anticoagulant drugs was associated with low hospitalization (5.8%) and mortality (0.2%) rates in a retrospective cohort of 392 Italian patients treated within the IppocrateOrg network.
DOI: 10.3390/jcm11206138